Anzeige
Mehr »
Donnerstag, 13.08.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P5N7 | ISIN: FI4000330972 | Ticker-Symbol: 4YL
Stuttgart
13.08.26 | 20:47
0,987 Euro
+1,23 % +0,012
Branche
Nanotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NANOFORM FINLAND OYJ Chart 1 Jahr
5-Tage-Chart
NANOFORM FINLAND OYJ 5-Tage-Chart
RealtimeGeldBriefZeit
0,9491,07821:03

Aktuelle News zur NANOFORM FINLAND Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.08.Nanoform Finland Oyj: Inside information: Positive Feedback from UK MHRA Scientific Advice Meeting regarding Nanoenzalutamide304Nanoform Finland Plc | Inside Information | August 05, 2026 at 12:00:00 EEST Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, announced today that it...
► Artikel lesen
19.05.Nanoform Finland Oyj: Nanoform Q1 2026 report - Record first quarter revenue, income and gross margin, first exclusivity deal signed around our Biologics technology799Nanoform Finland Plc | Company Release | May 19, 2026 at 08:10:00 EEST Record first quarter revenue, income and gross margin. Revenue grew by 45%, gross margin reached 94% and operating costs fell by...
► Artikel lesen
12.05.Nanoform Finland Oyj: Inside information: Nanoform Signs First Exclusivity Agreement for Ultra-High Concentration Subcutaneous Delivery755Nanoform Finland Plc | Inside Information | May 12, 2026 at 08:00:00 EEST Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it has...
► Artikel lesen
NANOFORM FINLAND Aktie jetzt für 0€ handeln
21.04.Nanoform Finland Oyj: Resolutions of Nanoform Finland Plc's Annual General Meeting on April 21, 2026583Nanoform Finland Plc | Company Release | April 21, 2026 at 12:20:00 EEST Nanoform Finland Plc (the "Company" or "Nanoform") held its Annual General Meeting for 2026 on April 21, 2026 at the Company's...
► Artikel lesen
02.03.Nanoform Finland Oyj: The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees910Nanoform Finland Plc | Company Release | March 02, 2026 at 08:10:00 EET Helsinki, Finland - The Annual General Meeting of Nanoform Finland Plc ("Nanoform") has on 15 April 2025 authorized the company's...
► Artikel lesen
26.02.Nanoform Finland Oyj: Nanoform Q4 & FY2025 report - Next: the submission of a marketing authorization application for Nanoenzalutamide in Europe829Nanoform Finland Plc | Company Release | February 26, 2026 at 08:10:00 EET Product kernel strategy continues to gain traction. Nanoenzalutamide: pivotal human fed and fasted study concluded, three more...
► Artikel lesen
07.01.Nanoform Finland Oyj: Inside information: Nanoform starts change negotiations as part of announced new midterm business targets for 2030831Nanoform Finland Plc | Inside Information | January 07, 2026 at 08:05:00 EET Helsinki, Finland - Nanoform Finland Plc ("Nanoform") starts change negotiations in accordance with the Act on Cooperation....
► Artikel lesen
16.12.25Nanoform Finland Oyj: Inside information: Nanoform announces new midterm business targets for 20301.654Nanoform Finland Plc | Inside Information | December 16, 2025 at 07:00:00 EET Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced new midterm...
► Artikel lesen
12.11.25Nanoform Finland Oyj: Nanoform Q3 report: Momentum in kernels continues, commercial cGMP manufacturing license received, first near-term target for 2026 set1.881Nanoform Finland Plc | Company Release | November 12, 2025 at 08:10:00 EET Our product kernels see good momentum. Nanoenzalutamide progresses with the fed arm of the pivotal human study. Licensing and...
► Artikel lesen
11.11.25Nanoform Finland Oyj: Inside information made public: Nanoform Granted European Commercial cGMP Manufacturing License1.025Nanoform Finland Plc | Inside Information | November 11, 2025 at 08:00:00 EET Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that...
► Artikel lesen
27.10.25Nanoform Finland Oyj: Nanoform Partners With Revio Therapeutics To Develop Long-Acting Locally-Delivered Hydrogel Nanoformulation To Treat Glioma1.009Nanoform Finland Plc | Press Release | October 27, 2025 at 09:10:00 EET Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced a partnership...
► Artikel lesen
14.10.25Nanoform Finland Oyj: Nanoform Outlicenses Nanoencorafenib And Signs Development And Commercialisation Agreement With A.forall And IMGA1.024Nanoform Finland Plc | Press Release | October 14, 2025 at 09:30:00 EEST Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it has...
► Artikel lesen
30.09.25Nanoform Finland Oyj: Nanoform Expands Commercial Presence In Asia With A&ls Pharma In South Korea1.070Nanoform Finland Plc | Press Release | September 30, 2025 at 09:30:00 EEST Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced it has entered...
► Artikel lesen
21.08.25Nanoform Finland Oyj: Nanoform Q2 2025 report: Continued progress on many fronts, supportive first preliminary pivotal nanoenzalutamide study results1.864Nanoform Finland Plc | Company Release | August 21, 2025 at 08:10:00 EEST First preliminary pivotal study results supportive for project Nanoenzalutamide to continue to progress towards the markets....
► Artikel lesen
14 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1